NCT03537690: FID-007 in Treating Participants With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have known untreated unstable brain metastasis; Patients who have received more than 3 prior lines of chemotherapy for advanced disease or prior treatment with paclitaxel or nab-paclitaxel; Patients who would receive paclitaxel (or nab-paclitaxel) as 1st line therapy in a tumor type in which paclitaxel (or nab-paclitaxel) has a proven survival benefit for metastatic disease

Comments are closed.

Up ↑